Centre of assisted reproduction, Shanghai East Hospital, Tongji University, Shanghai, People's Republic of China.
Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China.
Reprod Biol Endocrinol. 2018 May 28;16(1):53. doi: 10.1186/s12958-018-0373-7.
Oral progestin has recently been used to prevent premature LH surges in ovarian stimulation, and this progestin-primed ovarian stimulation (PPOS) is effective and safe in patients with different ovarian reserves. The current data are lacking regarding how to individualize the gonadotropin dose and regimen for women with polycystic ovarian syndrome (PCOS). A retrospective cohort trial was performed to evaluate the efficacy of progestin-primed milder stimulation with clomiphene citrate (CC) compared to the standard progestin-primed ovarian stimulation (PPOS) protocol for infertile women with PCOS.
A total of 220 PCOS women were collected and classified into the study group (HMG 150 IU/d + CC 50 mg/d + MPA 10 mg/d) and control group (HMG 225 IU/d + MPA 10 mg/d). Ovulation was triggered by GnRH agonist 0.1 mg and hCG 1000 IU when dominant follicles matured. Viable embryos were cryopreserved for later transfer. The primary endpoint was the ongoing pregnancy rate. Secondary outcomes included the cycle characteristics and the live birth rate.
RESULT(S): The study group consumed less HMG (1470.0 ± 360.1 IU vs 1943.8 ± 372.0 IU, P < 0.001) and harvested fewer oocytes than the control group (12.2 ± 7.4 vs 18.2 ± 9.7, P < 0.001). The study group showed a higher mid-follicular LH concentration (4.49 ± 2.49 mIU/ml vs 2.52 ± 2.09 mIU/ml, P < 0.05) but no endogenous LH surge. No between-group difference was found in the incidence of ovarian hyperstimulation syndrome (OHSS) (0.91% vs 0.91%, P > 0.05). The cumulative ongoing pregnancy rate and live birth rate per patient were lower but did not reach significance compared with the control group (71.8% vs 81.8 and 64.5% vs 75.5%, respectively, both P > 0.05).
CONCLUSION(S): The milder PPOS with CC in PCOS women led to lower oocyte yields and suboptimal pregnancy outcomes compared to the standard PPOS treatment. The two regimens both achieved a low incidence of OHSS. The results from the CC combination regimen provide a new insight for developing a more patient-friendly protocol for PCOS women.
口服孕激素最近被用于预防卵巢刺激中的 LH 过早激增,并且这种孕激素预处理的卵巢刺激(PPOS)在具有不同卵巢储备的患者中是有效且安全的。目前缺乏关于如何为多囊卵巢综合征(PCOS)患者个体化促性腺激素剂量和方案的信息。一项回顾性队列试验评估了氯米酚预处理轻度刺激与标准孕激素预处理卵巢刺激(PPOS)方案相比,对患有 PCOS 的不孕妇女的疗效。
共收集了 220 名 PCOS 妇女,分为研究组(HMG 150 IU/d+CC 50 mg/d+MPA 10 mg/d)和对照组(HMG 225 IU/d+MPA 10 mg/d)。当优势卵泡成熟时,通过 GnRH 激动剂 0.1 mg 和 hCG 1000 IU 触发排卵。将可存活的胚胎冷冻以备以后转移。主要终点是持续妊娠率。次要结局包括周期特征和活产率。
研究组使用的 HMG 较少(1470.0±360.1 IU 比 1943.8±372.0 IU,P<0.001),采集的卵子也少于对照组(12.2±7.4 比 18.2±9.7,P<0.001)。研究组卵泡中期 LH 浓度较高(4.49±2.49 mIU/ml 比 2.52±2.09 mIU/ml,P<0.05),但无内源性 LH 激增。两组卵巢过度刺激综合征(OHSS)的发生率无差异(0.91%比 0.91%,P>0.05)。与对照组相比,累积持续妊娠率和每位患者的活产率较低,但无统计学意义(分别为 71.8%比 81.8%和 64.5%比 75.5%,均 P>0.05)。
与标准 PPOS 治疗相比,CC 预处理的轻度 PPOS 导致 PCOS 妇女的卵母细胞产量较低和妊娠结局不理想。两种方案均实现了低 OHSS 发生率。CC 联合方案的结果为开发更适合 PCOS 患者的方案提供了新的思路。